A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154
about
Immune reconstitution in chronic lymphocytic leukemiaImmunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemiaLenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule.Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expressionHaematological malignancies: at the forefront of immunotherapeutic innovation.Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemiaAltered BCR and CD40 signalling are associated with clinical outcome in small lymphocytic lymphoma/chronic lymphocytic leukaemia and marginal zone lymphoma patientsChronic lymphocytic leukemia: an update on biology and treatment.Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches.Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment.Intratumoral injection of Ad-ISF35 (Chimeric CD154) breaks tolerance and induces lymphoma tumor regression.Immunotherapy for B-cell lymphoma: current status and prospective advancesChronic lymphocytic leukemia associated with immunotactoid glomerulopathy: a case report of successful treatment with high-dose methylprednisolone in combination with rituximab followed by alemtuzumab.The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia
P2860
Q26865561-E487CF67-0583-4D0E-9788-CD3100156F22Q27001318-0D18DF62-713B-453C-9222-816EC529490BQ33780253-068F0D08-65CA-4A42-AF77-C008F75A5AF4Q33965681-4C888E5E-D11D-4C34-BA58-407DBB2B8CA0Q35800342-0918028E-8B0B-4F60-AE2D-CBA95366866AQ35880618-3C879EE2-AEC0-4874-A2AF-9C622FC5384CQ36118111-B8F962BE-626A-48F5-B66B-1A5070DFBA9DQ37156943-5F3199BF-6037-4DD9-9B50-2050D8371475Q37902948-7D0CEEEF-5202-424B-A466-E44B0F08875FQ37910914-BC8F3221-E126-4056-B4C0-1D33EB06E284Q38110472-04E99472-844A-4057-B340-BA3FF8B5E1ADQ38941655-C3D02CED-6B27-41AB-B54A-D0012D819906Q41831989-CE404E3D-0124-48C8-B42D-D9EB3E9A2350Q43055766-2D05A6D4-7698-4227-9A9E-F114BC46C80EQ58042004-291F26B6-EEB9-4697-B99A-0207494DD4B7
P2860
A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
A phase I study of immune gene ...... mbrane-stable, humanized CD154
@ast
A phase I study of immune gene ...... mbrane-stable, humanized CD154
@en
type
label
A phase I study of immune gene ...... mbrane-stable, humanized CD154
@ast
A phase I study of immune gene ...... mbrane-stable, humanized CD154
@en
prefLabel
A phase I study of immune gene ...... mbrane-stable, humanized CD154
@ast
A phase I study of immune gene ...... mbrane-stable, humanized CD154
@en
P2093
P2860
P356
P1433
P1476
A phase I study of immune gene ...... mbrane-stable, humanized CD154
@en
P2093
C E Prussak
J E Castro
J McMannis
R Aguillon
W G Wierda
P2860
P2888
P304
P356
10.1038/LEU.2010.191
P577
2010-09-30T00:00:00Z